BRAF and neoplasm: The field has also seen an increase in tumor-agnostic therapy approvals linked to predictive biomarkers, including NTRK1/2/3 and RET fusions, BRAF V600E mutations, as well as genomic signatures for microsatellite instability (MSI) and tumor mutational burden (TMB) to identify patients who may benefit from immunotherapies.